

Seneca Fitch

MANAGING SCIENTIST

DIRECTOR, HEALTH SCIENCES

CONTACT INFORMATION

ToxStrategies, A BlueRidge Life Sciences Company
190 T C Jester Blvd., Suite 420
Houston, TX 77007
Phone (281) 377-6045
sfitch@toxstrategies.com

PROFESSIONAL PROFILE

Seneca Fitch, Director of ToxStrategies' Health Sciences practice, works as an information specialist and evidence analyst in support of systematic evaluations of substances associated with consumer products, food ingredients and additives, pharmaceuticals, and industrial chemicals. She has specialized expertise in facilitating the start-to-finish process of systematic reviews and evidence mapping according to several frameworks and utilizing software such as DistillerSR, HAWC, and SWIFTRReview. Such work includes problem formulation and protocol development, definition of eligibility criteria (i.e., inclusion/exclusion), data extraction parameters, critical appraisal of study quality, and creation of evidence tables and data visualizations. Additionally, Ms. Fitch has strong working knowledge of developing database-specific syntax and executing search strategies for investigational and systematic literature queries in citation databases such as PubMed, Embase, and ToxPlanet. This work consists of formulating search strings according to structured and controlled vocabulary, such as PubMed's MeSH and Embase's Emtree, using Boolean search phrases, and using reference management software to organize and deliver query results. Ms. Fitch also has extensive experience designing and implementing literature prioritization methods to address the growing landscape of scientific literature. This includes application of machine learning techniques such as topic modeling—an approach that uses text mining to identify patterns and information clusters within a set of references.

Ms. Fitch has applied the principals of systematic review, together with the evaluation of endocrine-disrupting potential, for multiple compounds by applying guidance such as ECHA/EFSA's 2018 Guidance for the identification of endocrine disruptors. These efforts include developing a strategy to gather and assess all relevant information, assemble lines of evidence, and integrate evidence for estrogen, androgen, thyroid, or steroidogenesis-related endocrine activity in developing overall conclusions. Data extraction for endocrine evaluation is implemented using specific processes and modality-specific templates that require a working knowledge of endpoints associated with each endocrine modality, as well as assignment to biological levels of organization and categories/levels of strength based on study design. Ms. Fitch routinely assesses endocrine-related data, as well as other data types, for quality via risk-of-bias and other validity tools, including NTP-OHAT, USEPA-TSCA, SciRAP, and ToxRTool.

In an extension of systematic evaluation, Ms. Fitch developed and maintains several internal and external platforms that consult a wide range of sources to combine data and assist in managing the scientific landscape—a capability that allows for efficient and timely summarizing of large amounts of information in qualitative and quantitative capacities. These databases include guidance levels developed for food additives by several regulatory agencies (e.g., Acceptable Daily Intakes [ADIs]), regulatory status of such additives, and results of toxicity and carcinogenicity studies for more than 1,800 chemical exposure studies. In addition to her skills in systematic review and literature identification, Ms. Fitch also has experience in the conduct of hazard assessments for a range of products, such as herbal and natural products, essential oils, food additives, and microorganisms. This includes identification of toxicological data, as well as integration of regulatory considerations from both US and international agencies to ensure a comprehensive overview of the product.

EDUCATION, TRAINING, AND CERTIFICATIONS

April 2020	DistillerSR Super User Certification
October 2019	EFSA/ECHA Guidance for Identifying Endocrine Disrupting Chemicals (Mainz, Germany)
May 2012	B.S., Biology, Texas Tech University, Lubbock, TX

PROFESSIONAL ACTIVITIES

October 2026	Speaker, University of Maryland JIFSAN Advisory Council Symposium: From Data to Decisions: AI Transforming Food Safety and Nutrition. Joint Institute for Food Safety and Applied Nutrition (JIFSAN) Center for Food Safety and Security Systems (SFS3), College Park, MD.
May 2026	Co-instructor, Webinar Series: Use of New Approach Methodologies in the Safety of Dietary Supplements-Parts One and Two. Council for Responsible Nutrition (CRN), Washington, DC.
March 2026	Instructor, Continuing Education Course PM10: Use Cases of Strategic Application of ML/AI in the Risk Assessment Process. Society of Toxicology 65 th Annual Meeting, San Diego, CA
2017–Present	Evidence Based Toxicology Collaboration Scientific Advisory Council (2019–present) Research Methods Working Group — Chair (2023–present) Tox21 Working Group Member
2020–Present	Association for Information Science and Technology
2015–2019	Air & Waste Management Association Young Professionals Coordinator (2016, 2017) Hot Air Topics Conference Planning Committee (2016) Annual Conference and Exhibition Planning Committee (2017)

SOFTWARE AND DATABASES

Systematic Review: DistillerSR, HAWC, SWIFT Review, SysRev

Data Visualization: Microsoft PowerBI, GraphPad Prism, Tableau, Microsoft Excel,

Literature Search: ToxPlanet, PubMed, Embase, *and others*

Reference Management: EndNote, Zotero, Mendeley

PROFESSIONAL EXPERIENCE

Designed and implemented a systematic evidence map case study using an AOP framework to characterize the potential estrogenicity of selected alkylphenols. The primary objective of this study was to characterize estrogen-mediated molecular initiating events, key events, key event relationships, and adverse outcomes for alkylphenols across evidence streams, species, and study designs.

Systematically evaluated potential endocrine activity (estrogen, androgen, thyroid, and steroidogenesis pathways) of oxybenzone, a common UV filter, across evidence streams using the EFSA/ECHA (2018) endocrine disruptor identification framework. This work included the use of the Microsoft Excel data extraction templates and line-of-evidence tables, to integrate data types for an overall characterization of evidence.

Collaborated in a weight-of-evidence analysis to evaluate the potential endocrine disruption activity across estrogen, androgen, thyroid, and steroidogenesis pathways of 6:2 FTOH and its degradant, PFHxA, by integrating *in vivo* studies and *in vitro* high-throughput screening data relative to the exposure required to elicit the potential responses.

Applied ECHA/EFSA (2018) guidance for evaluating endocrine disruptors to data sets for a variety of flame-retardants. The evaluations focused on identifying potential for activity along the estrogen, androgen, thyroid, and steroidogenesis pathways following exposure to these compounds, as well as any degradation products or metabolites.

Applied ECHA/EFSA (2018) guidance for evaluating endocrine disruptors to data sets for a proprietary insecticide to identify potential indicators of estrogen, androgen, thyroid, or steroidogenesis pathway disruption.

Implemented a scoping review based on the Joanna Briggs Institute framework (2015) to systematically map the literature landscape of when and how acceptable daily intakes of low-calorie sweeteners are compared to estimated intakes in nutrition research.

Systematically collected and updated relative potency estimates (REPs) for 29 dioxin-like compounds and designed a data selection hierarchy to identify highest quality data. The resulting database comprises >600 dose-response data sets (REPs) to facilitate the determination of TEFs quantitatively using all available data while accounting for quality, relevance, and a consistent approach.

Completed the analysis of multiple chemicals within SWIFT-Review to understand the efficiency with which the software organized and tagged the literature within specified toxicological categories.

Contributed to the development of multiple systematic review protocols, and their implementation, for a range of compounds (e.g., caffeine, TCE) across evidence streams (human, experimental animal, mechanistic). This included specific considerations such as establishing topic-specific search strategies, designating inclusion and exclusion criteria, study screening and characterization, and risk-of-bias assessment (e.g., internal validity). Protocols were developed according to the PROSPERO registration requirements to increase transparency and reduce bias in performing systematic reviews.

Developed a database to record and track ADI development by EFSA, JECFA, and FDA, and to benchmark values used to develop them. As a secondary initiative, subjective information, such as public opinion on the danger of such compounds, is also captured to provide a snapshot of the current landscape.

Collaborated in the development of a quantitative framework to evaluate the ten key characteristics of carcinogens, as described by Smith et al. (2016), in assessments of potential human carcinogens. In application, this framework involves applying a mathematical algorithm that allows for integration of data across characteristics and according to the quality, relevance, and activity to reach an overall conclusion about mechanistic data (as related to carcinogenicity).

Assisted in developing and implementing a search strategy to capture mechanistic data related to four common low-/no-calorie sweeteners. Data were then reviewed for relevance and extracted systematically, and an algorithm was applied to estimate carcinogenic potential relative to the ten key characteristics of carcinogens.

Formulated and conducted a systematic literature search to identify peer-reviewed literature pertaining to the carcinogenicity of a commonly used flame retardant. Screened literature by title and abstract and later organized results according to a framework utilized by IARC.

Regularly creates and pilots project-specific forms via DistillerSR, a proprietary software, according to the needs of title and abstract screening, full-text screening, data extraction, and risk of bias.

Regularly develops data visualizations using interactive software such as Tableau and PowerBI to support the characterization of project-specific literature landscapes.

Reviewed and extracted data from more than 600 publications to produce an index of data sets from *in vivo* and *in vitro* assays assessing the genotoxicity of 2-AAF, acrylamide, aflatoxin B₁, benzo(a)pyrene, butadiene, doxorubicin, MeIQx, PhIP, and vinyl chloride.

Assisted in compiling nonclinical pharmacology, pharmacokinetics, and toxicology data for the submission of a successful Investigational New Drug (IND) application filing.

Fit mathematical models to dose-response data using EPA's Benchmark Dose software to identify the benchmark dose level (BMDL) of a common flame retardant synergist.

Developed monographs for flavor additives and essential oils to identify relevant toxicology information and knowledge gaps for use in a large-scale systematic review of tobacco additives. Monographs included a review of available information, including physical and chemical properties, regulatory considerations, toxicological data, pyrolysis, and thermal degradation.

Wrote toxicology monographs identifying potential hazards of impurities and excipients at an anticipated exposure in patients for a pharmaceutical drug formulation. Assessments included physiochemical properties, regulated uses and limits, pharmacology, toxicology, immunology, pharmacokinetics, and in some cases, derivation of the toxicology-based exposure limit. Monographs were used to assess toxicity and formulate recommendations for necessary nonclinical studies.

Supported the update of an existing Superfund risk assessment using the EPA Risk Assessment Guidance for Superfund: Part D (RAGS D) tables to reflect potential new site usage.

Prepared a screening human health risk evaluation for indoor air measurements to assess the possibility of vapor intrusion of volatile organic compounds (VOCs) in subsurface soils adjacent to the property, and the potential public health risk of the current building and occupancy conditions. The data evaluation included comparison of indoor air concentrations to health-based screening levels and assessment of potential lifetime excess cancer risk and non-cancer hazard index of measured concentrations.

Formulated questions for a deposition pertaining to a potential occupational exposure to propane. Relevant questions were formed by an initial hazard characterization of propane, as well as site-specific information regarding the potential source of emission.

Calculated descriptive statistics of TBBPA and TBBPA-conjugate concentrations using GraphPad Prism to support analysis of the dose- and time-dependent changes of tissue levels in a repeat-dose toxicokinetic study.

Used the EPA IEUBK model to determine risk associated with soil concentrations of lead on a Superfund site in Pennsylvania for baseline and future/potential land-use scenarios.

Assisted in the development of a systematic review protocol and specific considerations, such as assessment of individual study risk of bias, or internal validity, as well as strength of evidence.

Conducted hazard assessments of natural products (e.g., chili peppers, marigold, etc.) intended for use in dietary supplements and other nutritional products. Assessments included review of traditional and current use, toxicological data, and various regulatory considerations from both US and international agencies.

Developed a chemical database for ToxStrategies that mines web data from more than 1,800 chemical exposure studies, facilitating trend analysis of continually accumulating intelligence pertaining to toxicity and carcinogenicity studies.

Assisted in generating receptor locations for air dispersion modeling of a chemical release, to obtain a data set that is sensitive to several possible exposure scenarios. Used this data set to compare identified air concentration limits, as well as values developed according to state guidance in a preliminary screening. Current emergency exposure limits were also evaluated in reference to the event in a preliminary health hazard assessment of the release.

Selected and compared defined Metropolitan Statistical Areas in the United States using data provided by the U.S. Census Bureau, to determine comparable cities based on similar demography and industrial workforce. These selected areas were used in an analysis of background health outcome levels to determine whether asthma and cancer rates are elevated among the cities of comparison.

Evaluated the geographic location of sediment samples along a shoreline with recreational access and assisted in identifying future sampling locations, to ensure an adequate amount of data to support future calculation of possible risks to visitors of the recreational sites.

BOOK CHAPTERS

Wikoff D, **Fitch S**. 2024. Evidence-based methods in toxicology: Systematic review and systematic evidence mapping. Chapter 32 in: Paustenbach DJ (ed), Human and Ecological Risk Assessment: Theory and Practice, Third Edition, [Wiley](#), pp. 1133–1148. ISBN: 978-1-119-74296-8.

Wikoff D, **Fitch S**. 2024. Systematic reviews and evidence-based methods in toxicology. In: Wexler P (ed), Encyclopedia of Toxicology. Elsevier, pp. 875–882.

MANUSCRIPTS

Buerger AN, Vincent MJ, **Fitch S**, Rivera B, Engel N, Zhang J, Rushton EK, Borghoff SJ. 2026. A mechanistic evaluation of the metabolism disrupting potential of methyl *tert*-butyl ether. *Curr Res Toxicol* 10(Apr 20):100290; doi: [10.1016/j.crtox.2026.100290](#).

Lea IA, Buerger AN, Vincent MJ,..., Choksi NY, Schaefer H, Britt J, **Fitch S**, Haws L, Borghoff SJ. 2026. Evaluating the potential carcinogenic hazard of diisononyl phthalate in humans via systematic integration of human, animal cancer studies, and mechanistic data. *Curr Res Toxicol* 10(Apr 30):100295; doi: [10.1016/j.crtox.2026.100295](#).

Borghoff SJ, Rivera B, **Fitch S**, Buerger AN, Choksi N, Franzen A, Vincent MJ, Covington T, Bus J, Rushton E, Lea IA. 2025. Systematic evaluation of the evidence base on methyl *tert*-butyl ether supporting a lack of concern for carcinogenic hazard in human based on animal cancer studies and mechanistic data. *Curr Res Toxicol* 8:100224; doi: [10.1016/j.crtox.2025.100224](#).

Fitch S, Rogers J, Marty S, Norman J, Schneider S, Rushton E, Wikoff D, Ellis-Hutchings R. 2025. Systematic review of potential developmental and reproductive toxicity of microplastics. *Toxicol Sci* 207(2):289-305; doi: [10.1093/toxsci/kfaf108](#).

Kennedy SB, Heintz MM, Klaren WD, Wikoff DS, Haws LC, **Fitch SE**. 2025. An integrated ecotoxicological study reliability framework for use in toxicity value development. *Environ Tox Chem* 44(4):1142-1153; doi: [10.1093/etojnl/vgaf030](#).

Rivera BN, Lea IA, **Fitch S**, Choksi N, Franzen A, Bus J, Rushton E, Borghoff SJ. 2025. Systematic evaluation of the evidence base on ethyl *tert*-butyl ether and *tert*-butyl alcohol for carcinogenic potential in humans: Lack of

concern based on animal cancer studies and mechanistic data. *Curr Res Tox* 10(Nov 10):100270; doi: [10.1016/j.crttox.2025.100270](https://doi.org/10.1016/j.crttox.2025.100270).

Fitch S, Blanchette A, Haws LC, Franke K, Ring C, DeVito M, ... Wikoff DS. 2024. Systematic update to the mammalian relative potency estimate database and development of best estimate toxic equivalency factors for dioxin-like compounds. *Regul Toxicol Pharmacol* 147:105571; doi: [10.1016/j.yrtph.2024.105571](https://doi.org/10.1016/j.yrtph.2024.105571).

Vincent MJ, **Fitch S**, Bylsma L, Thompson C, Rogers S, Britt J, Wikoff D. 2024. Assessment of associations between inhaled formaldehyde and lymphohematopoietic cancer through the integration of epidemiological and toxicological evidence with biological plausibility. *Toxicol Sci* 199(2):172–193. [Open access](#).

Borghoff SJ, **Fitch SE**, Black MVB, McMullen PD, Andersen ME, Chappell GA. 2021. A systematic approach to evaluate plausible modes of [action] for mouse lung tumors in mice exposed to 4-methylimidazole. *Regul Toxicol Pharmacol* 124:104977; doi: [10.1016/j.yrtph.2021.104977](https://doi.org/10.1016/j.yrtph.2021.104977).

Dirven H, Vist GE, Bandhakavi S, Mehta J, **Fitch SE**, Pound P, Ram R, Kincaid B, et al. 2021. Performance of preclinical models in predicting drug-induced liver injury in humans: A systematic review. *Sci Reports* 11(1):6403; doi: [10.1038/s41598-021-85708-2](https://doi.org/10.1038/s41598-021-85708-2). [Open access](#).

Fitch SE, Payne LE, van de Ligt JLG, Doepker C, Handu D, Cohen SM, Anyangwe N, Wikoff D. 2021. Use of acceptable daily intake (ADI) as a health-based benchmark in nutrition research studies that consider the safety of low-calorie sweeteners (LCS): A systematic map. *BMC Public Health* 21(1):956, doi: [10.1186/s12889-021-10934-2](https://doi.org/10.1186/s12889-021-10934-2).

Thompson CM, Gentry R, **Fitch S**, Lu K, Clewell HJ. 2020. An updated mode of action and human relevance framework evaluation for formaldehyde-related nasal tumors. *Crit Rev Toxicol* 50(10):919–952; doi: [10.1080/10408444.2020.1854679](https://doi.org/10.1080/10408444.2020.1854679).

Wikoff DS, Urban JD, Ring C, Britt J, **Fitch S**, Haws LC. 2020. Development of a range of plausible non-cancer toxicity values for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) based on effects on sperm count: Application of systematic review methods and quantitative integration of dose response using meta-regression. *Toxicol Sci* 179(2):162–182; doi: [10.1093/toxsci/kfaa171](https://doi.org/10.1093/toxsci/kfaa171).

Suh M, Wikoff D, Lipworth L, Goodman M, **Fitch S**, Mittal L, Ring C, Proctor D. 2019. Hexavalent chromium and stomach cancer: A systematic review and meta-analysis. *Crit Rev Toxicol* 49(2):140–159. doi: [10.1080/10408444.2019.1578730](https://doi.org/10.1080/10408444.2019.1578730).

Thompson CM, **Fitch SE**, Ring C, Rish W, Cullen JM, Haws LC. 2019. Development of an oral reference dose for the perfluorinated compound GenX. *J Appl Toxicol* 39(9):1267–1282; doi: [10.1002/jat.3812](https://doi.org/10.1002/jat.3812).

Wikoff DS, Chappel GA, **Fitch S**, Doepker CL, Borghoff SJ. 2019. Lack of potential carcinogenicity for aspartame—Systematic evaluation and integration of mechanistic data into the totality of the evidence. *Food Chem Toxicol* 135:110866; doi: [10.1016/j.fct.2019.110866](https://doi.org/10.1016/j.fct.2019.110866).

Borghoff SJ, **Fitch S**, Rager JE, Huggett D. 2018. A hypothesis-driven weight-of-evidence analysis to evaluate potential endocrine activity of perfluorohexanoic acid. *Regul Toxicol Pharmacol* 99:168–181.

Thompson CM, Kirman CR, Hays SM, Suh M, **Harvey SE**, Proctor DM, Rager JE, Haws LC, Harris MA. 2018. Integration of mechanistic and pharmacokinetic information to derive oral reference dose and margin-of-exposure values for hexavalent chromium. *J Appl Toxicol* 38:351–365. doi: [10.1002/jat.3545](https://doi.org/10.1002/jat.3545).

Wikoff DS, Rager JE, Chappell GA, **Fitch S**, Haws L, Borghoff SJ. 2018. A framework for systematic evaluation and quantitative integration of mechanistic data in assessments of potential human carcinogens. *Toxicol Sci* 167(2):322–335, <https://doi.org/10.1093/toxsci/kfy279>.

Wikoff DS, Thompson C, Rager J, Chappell G, **Fitch S**, Doepker C. 2018. Benefit-risk analysis for foods (BRAFO): Evaluation of exposure to dietary nitrates. *Food Chem Toxicol* 120:709–723; doi: [10.1016/j.fct.2018.08.031](https://doi.org/10.1016/j.fct.2018.08.031).

Wikoff D, Urban JD, **Harvey S**, Haws LC. 2018. Role of risk of bias in systematic review for chemical risk assessment: A case study in understanding the relationship between congenital heart defects and exposures to trichloroethylene. *Int J Toxicol* 37(2):125-143; doi: 10.1177/1091581818754330.

Thompson CM, Kirman CR, Hays SM, Suh M, **Harvey SE**, Proctor DM, Rager JE, Haws LC, Harris MA. 2017. Integration of mechanistic and pharmacokinetic information to derive oral reference dose and margin-of-exposure values for hexavalent chromium. *J Appl Toxicol* 38:351-365; doi: 10.1002/jat.3545.

Wikoff D, Welsh BT, Henderson R, Brorby GP, Britt J, Myers E, Goldberger J, Lieberman HR, O'Brien C, Peck J, Tenebein M, Weaver C, **Harvey S**, Urban J, Doepker C. 2017. Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. *Food Chem Toxicol* 109(Pt1):585-648; doi: 10.1016/j.fct.2017.04.002.

Borghoff SJ, Wikoff D, **Harvey S**, Haws L. 2016. Dose- and time-dependent changes in tissue levels of tetrabromobisphenol A (TBBPA) and its sulfate and glucuronide conjugates following repeated administration to female Wistar Han rats. *Toxicol Reports* 3:190-201; doi: 10.1016/j.toxrep.2016.01.007.

ABSTRACTS AND PRESENTATIONS

Buerger AN, Lea IA, Vincent MJ, Rivera BN, Choksi NY, Britt J, **Fitch S**, Rogers S, et al. Systematic evaluation of the carcinogenic potential of di-isononyl phthalate in humans. Abstract 3314, Society of Toxicology 65th Annual Meeting, San Diego, CA, March 2026.

Shobair M, Allen D, Ballone I, Brull M, Burbank M, Choksi N, **Fitch S**, Irizar A, et al. A machine-learning approach for the development of a knowledgebase to identify systemic toxicity mechanistic targets and evaluate biological space coverage. Abstract 5161, Society of Toxicology 65th Annual Meeting, San Diego, CA, March 2026.

Vincent M, Wheeler M, Schaefer H, Rhoden J, **Fitch S**, Wikoff D. Quantitative bias assessment to facilitate assessment of (un)certainty in observational data evaluating acetaminophen use and liver cancer. Abstract 4279, Society of Toxicology 65th Annual Meeting, San Diego, CA, March 2026.

Wikoff D, **Fitch S**, Eichenbaum G, Ejaz S, Klaren W, Southall M. Need for fit-for-purpose approaches that integrate dose, mechanism, and context of use with key characteristics when evaluating the carcinogenic potential of widely used therapeutics: A case study of acetaminophen. Abstract 4005, Society of Toxicology 65th Annual Meeting, San Diego, CA, March 2026.

Borghoff SJ, Rivera BN, **Fitch S**, Buerger A, Choksi N, Franzen A, Bus J, Rushton EK, Lea I. Systematic evaluation of the evidence base on methyl tert-butyl ether for carcinogenic potential in humans; Low concern based on animal cancer studies and mechanistic data. Abstract 4702, Society of Toxicology 64th Annual Meeting, Orlando, FL, March 2025.

Buerger AN, Vincent MJ, **Fitch S**, Rushton EK, Borghoff SJ. Evaluation of potential obesogenicity through a mode of action approach: A case study with MTBE. Abstract 3928, Society of Toxicology 64th Annual Meeting, Orlando, FL, March 2025.

Fitch S, Wikoff D, Foreman J, Buerger A, Haws L, Palmero C. Assessment of relative potency factors for six phthalates. Abstract 4235, Society of Toxicology 64th Annual Meeting, Orlando, FL, March 2025

Fitch S. Streamlining systematic reviews through pragmatic problem formulation and literature prioritization. Roundtable session: Is it time to right-size systematic review? Society of Toxicology 64th Annual Meeting, Orlando, FL, March 2025.

Rivera BN, Lea IA, **Fitch S**, Choksi N, Franzen A, Bus J, Rushton EK, Borghoff SJ. Systematic evaluation of the evidence base on ethyl tert-butyl ether and tert-butyl alcohol for carcinogenic potential in humans: Low concern based on animal cancer studies and mechanistic data. Abstract 4697, Society of Toxicology 64th Annual Meeting, Orlando, FL, March 2025.

Wikoff D, **Fitch S**, Vincent M, Southall MD, Atillasoy E, Weinstein RD, Ejaz SD, Rhoden JD, Choksi N. Biological plausibility assessment of acetaminophen and occurrence of developmental neurological outcomes in humans. Abstract 4768, Society of Toxicology 64th Annual Meeting, Orlando, FL, March 2025.

Fitch S, Ellis-Hutchings R, Rogers J, Marty S, Rushton E, ... Wikoff D. Study quality evaluation of literature reporting plastic microparticle exposure against reproductive and developmental toxicity endpoints. Abstract 5159, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Lynn SG, Lea IA, Urban J, Borghoff SJ, Wikoff D, **Fitch S**, Perry C, Choksi N, Britt J, Heintz M, Klaren W, et al. Development and application of systematic approach to inventory and interrogate thyroid hormone network information. Abstract 4357, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Thompson CM, Heintz MM, Rogers SI, **Fitch SE**, Rivera BN, Klaren WD, Vincent MJ, Wikoff DS, Haws LC. Evidence identification and appraisal supporting development of an updated toxicity value for HFPO-DA. Abstract 3654, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Urban JD, Covington TR, **Fitch SE**, Wikoff DS. Dioxin-like compounds in soils: A pilot survey updating background soil TEQ. Abstract 5147, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Vincent M, **Fitch S**, Bylsma L, Thompson C, Rogers S, Britt J, Wikoff D. Integration of toxicological and epidemiological information to evaluate biological plausibility and causality of associations between inhaled formaldehyde (FA) and lymphohematopoietic (LHP) cancers. Abstract 5157, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Choksi NY, **Fitch S**, Harris MA, Thompson CM, Wikoff DS. Reliability assessment of guideline-based studies using systematic review critical appraisal tools. Poster presented at Society of Toxicology 62nd Annual Meeting, Nashville, TN, March 2023.

Fitch S, Rogers J, Marty S, Ellis-Hutchings R, Becker R, Wikoff D. Development of a study quality tool for use in a systematic review of literature reporting microplastic exposure and reproductive and developmental toxicity. Poster presented at Society of Toxicology 62nd Annual Meeting, Nashville, TN, March 2023.

Fitch S, Klaren WD, Payne L, Wikoff D. Comparison of public and private literature databases for toxicological investigations. Poster presented at Society of Toxicology 61st Annual Meeting, San Diego, CA, March 2022.

Wikoff D, Edwards S, Angrish M, Baumgartner, Bever R, Borghoff S, Chappell G, Chew R, **Fitch S**, Hench G, Hamernik K, Henderson D, Kirk A, Lea I, Mandel M, Payne L, Shapiro S, Urban J, Williams D, Markey K. Application of systematic methods to characterize thyroid adverse outcome pathways (AOPs). Presented at American Society for Cellular and Computational Toxicology 10th Annual Meeting, Virtual, October 2021.

Fitch S, Goyak K, Green M, Grimm F, Wikoff D. AOP-based evidence integration in risk assessment: An evidence mapping case study on the estrogenicity of alkylphenols. Presentation at Society of Toxicology 59th Annual Meeting, Virtual, March 2020.

Ring C, Wikoff DS, Urban J, **Fitch S**, Haws LC. Survey of case studies in application of approaches for quantitative evidence integration and uncertainty analysis. Presentation at Society of Toxicology 59th Annual Meeting, Virtual, March 2020.

Ring C, **Fitch S**, Haws L, Harris M, Wikoff D. Quantitative integration of dose-response data for relative potency estimates of dioxin-like chemicals. Poster for Society of Toxicology, 59th Annual Meeting, Virtual, March 2020.

Grimm FA, Goyak KO, Qian H, **Fitch S**, Wikoff D, Alexander MS, Lewis RJ. Advancing chemical safety assessments using multivariate evidence integration: A systematic evidence map on estrogenicity of alkylphenols. Poster for Workshop on Evidence Integration, University of Ottawa, Ottawa, Canada, December 2019.

Fitch S, Wikoff D, Franke K, Ring C, Harris M, Haws L. Systematic update of the mammalian relative potency estimate (REP) database for dioxin-like compounds (DLCs). Poster for DIOXIN: 39th International Symposium on Halogenated Persistent Organic Pollutants, Kyoto, Japan, August 2019.

Urban J, Wikoff D, **Fitch S**, Ring C, Haws L, Harris M. An evaluation of the utility of human cell models for characterizing relative potency for dioxin-like compounds. Poster for DIOXIN: 39th International Symposium on Halogenated Persistent Organic Pollutants, Kyoto, Japan, August 2019.

Borghoff S, **Fitch S**, Britt J, Franke K, Wikoff D. Application of the EFSA/ECHA endocrine disruption guidance as a framework for evidence integration in a weight-of-evidence (WoE) analysis for oxybenzone (BP-3). Poster at Evidence Integration in Chemical Assessments: Challenges Faced in Developing and Communicating Human Health Effect Conclusions, National Academies of Sciences, Engineering, and Medicine, Washington, DC, June 2019.

Fitch S, Wikoff D, Franke K, Ring C, Harris M, Haws L. Systematic update of the mammalian relative potency estimate (REP) database for dioxin-like compounds (DLCs). IUTOX 15th International Congress of Toxicology, Honolulu, HI, July 2019.

Urban J, Wikoff D, **Fitch S**, Ring C, Haws L, Harris M. An evaluation of the utility of human cell models for characterizing relative potency for dioxin-like compounds. IUTOX 15th International Congress of Toxicology, Honolulu, HI, July 2019.

Urban J, Wikoff D, Suh M, Britt J, **Harvey S**, Chappell G, Haws L. Comparison of NTP OHAT and US EPA TSCA study quality criteria: Trichloroethylene (TCE) and congenital heart defects (CHDs) as a case study. Poster at Society of Toxicology 58th Annual Meeting, Baltimore, MD, March 2019.

Borghoff SJ, **Fitch S**, Huggett, Wikoff D. A hypothesis-driven weight-of-evidence analysis to evaluate potential endocrine disrupting properties of perfluorohexanoic acid (PFHxA). Poster at Society of Toxicology 58th Annual Meeting, Baltimore, MD, March 2019.

Urban JD, **Harvey S**, Haws LC, Wikoff D. Assessment of study quality (risk of bias) in understanding the relationship between congenital heart defects (CHDs) and exposures to trichloroethylene (TCE). Society of Toxicology 57th Annual Meeting, San Antonio, TX, March 2018.

Chappell G, Welsh B, **Harvey S**, Harris M, Wikoff D. Validation and application of a text mining tool for identification and categorization of mechanistic data related to the key characteristics of carcinogens: Case studies of a problem formulation tool. Presented at the Society for Risk Analysis Annual Meeting, Arlington, VA, December 2017.

Wikoff DS, Rager JE, **Harvey S**, Haws L, Chappell G, Borghoff S. Development and refinement of a framework for quantitative consideration of study quality and relevance in the evaluation of mechanistic data based on key characteristics of carcinogens. Society of Risk Analysis Annual Meeting, Arlington, VA, December 2017.

Huggett D, **Harvey S**, Korzeniowski S, Borghoff S. The potential for 6:2 FTOH to modulate the endocrine system in wildlife: A hypothesis driven weight of evidence analysis across endocrine pathways. Presented at the Society of Environmental Toxicology and Chemistry 38th Annual Meeting, Minneapolis, MN, November 2017.

Borghoff S, **Harvey S**, Korzeniowski S, Huggett D. The potential for PFHxA to modulate the endocrine system in wildlife: A hypothesis driven weight of evidence analysis across endocrine pathways. Presented at the Society of Environmental Toxicology and Chemistry 38th Annual Meeting, Minneapolis, MN, November 2017.

Suh M, **Harvey S**, Wikoff D, Mittal L, Ring C, Goodmanson A, Proctor D. Meta-analysis of hexavalent chromium and stomach cancer. Presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

Chappell G, Welsh B, **Harvey S**, Harris M, Wikoff D. Validation and application of a text mining tool in the identification and categorization of mechanistic data: A case study in improving problem formulation for carcinogenicity assessments. Presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

Wikoff DS, Rager J, **Harvey S**, Haws L, Chappell G, Borghoff S. Framework for quantitative consideration of study quality and relevance in the systematic evaluation of mechanistic data per the ten key characteristics of carcinogens. Risk Assessment Specialty Section Top Ten Abstract. Presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

Doepker C, Tyndall K, Lane R, Wikoff D, Thompson C, **Harvey S**, Schmitt D. A proposed ADI for nitrate. Presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

PROTOCOLS

Fitch S, Goyak K, Green M, Grimm F, Wikoff D. 2019. Estrogen-mediated outcomes for alkylphenols via an adverse outcome pathway (AOP) construct. Open Science Framework, August, <https://osf.io/dwg4c/>.

Fitch S, van de Ligt J, Payne L, Doepker C, Kleinman R, Handu D, Cohen SM, Anyangwe N, Wikoff D. 2019. Systematic map protocol: A systematic map of the use of acceptable daily intake (ADI) as a health-based benchmark in nutrition research studies that consider the safety of low-calorie sweeteners (LCS). Open Science Framework, <https://osf.io/6x3ks/>.

Urban J, Wikoff D, Haws L, **Fitch S**, Ring C, Thompson C, Suh M. 2018. Systematic review protocol: Systematic review and meta-regression to characterize the dose-response relationship between exposure to dioxin-like compounds during sensitive windows of development and reduced sperm count. Zenodo. <http://doi.org/10.5281/zenodo.1636357>.

Tsaion K, Dirven H, Beck Færden K, Wikoff D, Ram R, Kleinstreuer N, McCormack A, Wright R, Vist GE, **Fitch S**. 2018. Systematic reviews of the hepatotoxic effects of specified compounds/drugs as observed in humans and experimental animals (rats, mice, dogs and non-human primates). PROSPERO. Available at: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018112353.

Wikoff D, Suh M, **Harvey S**, Proctor D, Beretvas T, Goodman M, Lipworth L. 2016. Systematic review and meta-analysis of occupational exposure to Cr(VI) and stomach cancer. PROSPERO 2016:CRD42016051625 Available from http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016051625 (Systematic Review Protocol Registration).

Wikoff D, Borghoff S, Rager J, **Harvey S**, Haws L. 2016. A systematic review of the mechanistic evidence of tetrabromobisphenol A (TBBPA) as a human carcinogen according to the ten key characteristics of carcinogens (TKCC) identified by Smith et al. (2016). PROSPERO 2016:CRD42016046429.

Wikoff D, Doepker C, Welsh B, Urban J, Henderson R, Brorby G, Britt J, **Harvey S**, Goldberger J, Myers E, O'Brien C, Peck J, Lieberman H, Weaver C, Tenebein M. 2015. Systematic review of the adverse cardiovascular effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. PROSPERO 2015:CRD42015026673.

Wikoff D, Doepker C, Welsh B, Urban J, Henderson R, Britt J, **Harvey S**, Goldberger J, Myers E, O'Brien C, Peck J, Lieberman H, Weaver C, Tenebein M. 2015. Systematic review of the adverse bone and calcium balance effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. PROSPERO 2015:CRD42015026609.

Wikoff D, Doepker C, Welsh B, **Harvey S**, Goldberger J, Lieberman H, Myers E, O'Brien C, Peck J, Tenebein M, Urban J, Weaver C. Systematic review of the adverse reproductive and developmental effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. PROSPERO 2015:CRD42015026736. Available from http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015026736 (Systematic Review Protocol Registration).

Wikoff D, Doepker C, Welsh B, **Harvey S**, Goldberger J, Lieberman H, Myers E, O'Brien C, Peck J, Tenebein M, Urban J, Weaver C. Systematic review of acute adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. PROSPERO 2015:CRD42015026704. Available from http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015026704 (Systematic Review Protocol Registration).